Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; the references it cites are not checked yet.

Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer’s disease

Open access
Morris, Gary P., Clark, Ian A., Vissel, Bryce·2018·Acta Neuropathologica

Abstract

The dominant hypothesis of Alzheimer's disease (AD) aetiology, the neuropathological guidelines for diagnosing AD and the majority of high-profile therapeutic efforts, in both research and in clinical practice, have been built around one possible causal factor, amyloid-β (Aβ). However, the causal link between Aβ and AD remains unproven. Here, in the context of a detailed assessment of historical and contemporary studies, we raise critical questions regarding the role of Aβ in the definition, diagnosis and aetiology of AD. We illustrate that a holistic view of the available data does not support an unequivocal conclusion that Aβ has a central or unique role in AD. Instead, the data suggest alternative views of AD aetiology are potentially valid, at this time. We propose that an unbiased way forward for the field, beyond the current Aβ-centric approach, without excluding a role for Aβ, is required to come to an accurate understanding of AD dementia and, ultimately, an effective treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00401-018-1918-8

Cites

Statistics

Figures

Fig. 1 A chronological sequence of questions, assumptions and findings leading to the current Aβ-centric ‘consensus’ Alzheimer’s disease neuropathological diagnostic guidelines. Major observations, findings and assumptions have been distilled into the current ‘consensus’ diagnostic guidelines for AD. In brief, these guidelines are derived from the hypothesis that the relative levels of amyloid plaques and NFTs in specific brain regions differentiates AD dementia from normal cognitive aging. Combined with the amyloid hypothesis they predict Aβ and tau pathology to be a specific marker of AD at symptomatic and possibly preclinical and prodromal stages, with Aβ considered causative of tau pathology (and other AD-associated pathologies). NFTs neurofibrillary tangles, Aβ amyloid-β
Fig. 1 A chronological sequence of questions, assumptions and findings leading to the current Aβ-centric ‘consensus’ Alzheimer’s disease neuropathological diagnostic guidelines. Major observations, findings and assumptions have been distilled into the current ‘consensus’ diagnostic guidelines for AD. In brief, these guidelines are derived from the hypothesis that the relative levels of amyloid plaques and NFTs in specific brain regions differentiates AD dementia from normal cognitive aging. Combined with the amyloid hypothesis they predict Aβ and tau pathology to be a specific marker of AD at symptomatic and possibly preclinical and prodromal stages, with Aβ considered causative of tau pathology (and other AD-associated pathologies). NFTs neurofibrillary tangles, Aβ amyloid-βCC BY · PubMed Central
Fig. 2 The missing pieces of the puzzle in the chronological sequence of questions, assumptions and findings that lead to the current Aβ-centric ‘consensus’ Alzheimer’s disease diagnostic guidelines. Many problems with the evidence used to support the current consensus diagnostic guidelines and the amyloid hypothesis still exist. 1. Aβ pathology does not correlate well spatially to areas undergoing atrophy. 2. Other pathologies correlate better (synapses, NFTs) but have not been as extensively studied. 3. Early-onset AD and late-onset AD might be different diseases based on evidence suggesting they can be distinguished in various ways. 4. AD may not be one single homogenous disorder. 5. Aβ pathology exists in cognitively normal individuals. 6. Aβ pathology is lacking in some with AD dementia. 7. Aβ pathology is not unique to AD dementia. 8. It is not conclusive that Aβ pathology is, temporally, the first ‘biomarker’ of AD. 9. Deleterious mutations in many genes can be linked to Aβ, but not all of them necessarily mechanistically contribute to disease through an effect on Aβ metabolism. 10. Protective environmental and genetic factors are not necessarily mechanistically protective through some effect on Aβ. 11. Much of the genetics of familial AD remains unresolved. 12. Senescence, autophagy, genetic, microbial, lifestyle choices/environmental and cardiovascular/traumatic injury risk factors are potential upstream ‘causes’ of AD, but their mechanism contribution to pathogenesis is not necessarily through Aβ. 13. Apart from genetics, most evidence supporting the amyloid hypothesis comes from preclinical research (toxicity studies, expression of human AD mutations in mice), much of which has dubious relevance to the human condition [179]. 14. Many valid alternate hypotheses of AD aetiology exist. 15. Many other possible factors independent of Aβ that could provide clues to causality exist. 16. Other methods for defining disease in preclinical, prodromal and symptomatic stages that do not require a priori stratification on the basis of Aβ measurement may exist, and remain untested. NFTs neurofibrillary tangles, Aβ amyloid-β
Fig. 2 The missing pieces of the puzzle in the chronological sequence of questions, assumptions and findings that lead to the current Aβ-centric ‘consensus’ Alzheimer’s disease diagnostic guidelines. Many problems with the evidence used to support the current consensus diagnostic guidelines and the amyloid hypothesis still exist. 1. Aβ pathology does not correlate well spatially to areas undergoing atrophy. 2. Other pathologies correlate better (synapses, NFTs) but have not been as extensively studied. 3. Early-onset AD and late-onset AD might be different diseases based on evidence suggesting they can be distinguished in various ways. 4. AD may not be one single homogenous disorder. 5. Aβ pathology exists in cognitively normal individuals. 6. Aβ pathology is lacking in some with AD dementia. 7. Aβ pathology is not unique to AD dementia. 8. It is not conclusive that Aβ pathology is, temporally, the first ‘biomarker’ of AD. 9. Deleterious mutations in many genes can be linked to Aβ, but not all of them necessarily mechanistically contribute to disease through an effect on Aβ metabolism. 10. Protective environmental and genetic factors are not necessarily mechanistically protective through some effect on Aβ. 11. Much of the genetics of familial AD remains unresolved. 12. Senescence, autophagy, genetic, microbial, lifestyle choices/environmental and cardiovascular/traumatic injury risk factors are potential upstream ‘causes’ of AD, but their mechanism contribution to pathogenesis is not necessarily through Aβ. 13. Apart from genetics, most evidence supporting the amyloid hypothesis comes from preclinical research (toxicity studies, expression of human AD mutations in mice), much of which has dubious relevance to the human condition [179]. 14. Many valid alternate hypotheses of AD aetiology exist. 15. Many other possible factors independent of Aβ that could provide clues to causality exist. 16. Other methods for defining disease in preclinical, prodromal and symptomatic stages that do not require a priori stratification on the basis of Aβ measurement may exist, and remain untested. NFTs neurofibrillary tangles, Aβ amyloid-βCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 304 · Cited by 212

Research works printed but not linked: 1

  1. Eisai and Biogen (2018) Eisai and Biogen announce detailed results of phase II clinical study of BAN2401. In: Early Alzheimer’s disease at Alzheimer’s association international conference (AAIC) 2018. http://investors.biogen.com/news-releases/news-release-details/eisai-and-biogen-announce-detailed-results-phase-ii-clinical . Accessed 27 Sept 2018

Metadata

Authors
Morris, G. P., Clark, I. A., & Vissel, B.
Affiliations
  • University of Technology Sydney (AU)
  • Australian National University (AU)
Corresponding author
Vissel, Bryce
Venue
Acta Neuropathologica
Published
2018-10-22
Volume
136
Issue
5
Pages
663-689
ISSN
  • 0001-6322 (ISSN-L)
  • 1432-0533
OpenAlex
W2896396037
Cited by
212
References
304
Citations by year
2026: 14 · 2025: 20 · 2024: 29 · 2023: 30 · 2022: 19 · 2021: 33 · 2020: 35 · 2019: 29 · 2018: 3
FWCI
3.28
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0 (tdm)
Locations
  • Acta Neuropathologica (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ANU Open Research (Australian National University) (submittedVersion, cc-by)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, amyloid-beta, amyloid hypothesis, etiology, disease definition, dementia, Alzheimer's disease treatment
MeSH terms
Alzheimer Disease, Animals, Humans, Amyloid beta-Peptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer’s disease. https://app.cochat.ai/papers/10.1007/s00401-018-1918-8
The paper
Morris, G. P., Clark, I. A., & Vissel, B. (2018). Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer’s disease. Acta Neuropathologica. https://doi.org/10.1007/s00401-018-1918-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.